Use of defibrotide in the treatment of acute myocardial infarction.
The results of this preliminary clinical trial confirm the thrombolytic effect of defibrotide demonstrated in preclinical models; demonstrate the positive influence of the product on the natural history of early AMI; suggest that the optimal dosage range should include not less than 1.6 gm of defibrotide during the first hour of treatment; and justify further commitment in the study of defibrotide also beyond the scope of treating AMI.
Milazzotto
F
F
Coronary Care Unit, Echocardiography Service, S. Camillo Hospital, Rome, Italy.
Carelli
M
M
Citone
C
C
Di Marcotullio
G
G
Giampaolo
P
P
Malinconico
U
U
Polizzi
C
C
Tubaro
M
M
Giovannini
E
E
Boccardi
L
L
D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D015425:Myocardial Reperfusion; D009336:Necrosis; D011089:Polydeoxyribonucleotides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide